GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Marksans Pharma Ltd

Marksans Pharma Acquires ABCnow GmbH for € 892,384

M&A ▲ Positive Development LOW RISK
📅 Filed on BSE: 08 Jul 2026, 10:07 AM IST  ·  BSE ID: 291aa7ad-d6be-4e03-9fd2-cab440d8b217
View Original BSE Filing (PDF)
💡
In Simple Terms
Marksans Pharma is buying a German drug distribution company, ABCnow GmbH, for € 892,384 to boost its European market access.
🤖 AI Summary
  • Marksans Pharma agreed to acquire 100% share capital of Germany-based ABCnow GmbH for € 892,384 cash.
  • ABCnow GmbH is a pharmaceutical wholesale and distribution company with front-end sales in Germany.
  • The acquisition expands Marksans' presence in regulated European markets and strengthens its forward integration.
  • ABCnow GmbH had a turnover of € 227,233.69 as on December 31, 2025.
  • The transaction is anticipated to be completed by July 31, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Cost
€ 892,384
ABCnow GmbH Turnover (as on Dec 31, 2025)
€ 227,233.69
Not comparable — limited prior period data.
ABCnow GmbH Turnover (2024)
€ 510,215.60
Share Capital Acquired
100%
🏢 How This Affects the Company
📈
Business Impact
This acquisition enables Marksans Pharma to utilize ABCnow GmbH's front-end sales and marketing infrastructure for its products in Germany, enhancing its direct market access in the European Union.
💰
Financial Impact
The acquisition involves a cash consideration of € 892,384, impacting Marksans Pharma's cash reserves. ABCnow GmbH's turnover was € 227,233.69 as on December 31, 2025.
⚙️
Operational Impact
Marksans Pharma will establish its own front end in Germany through ABCnow GmbH, integrating its products manufactured in India, UK, and USA into German distribution channels.
⚠️
Risk Impact
The filing states no governmental or regulatory approvals are required for the acquisition, which reduces execution risk for the transaction.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders concerning this acquisition announcement.
👤
Who Is Affected
Marksans Pharma shareholders are affected by the company's strategic expansion into Germany via a € 892,384 cash acquisition, potentially altering the company's asset base and future revenue streams.
🔍
Management Signal
This decision signals management's intent to strengthen Marksans Pharma's presence in regulated European markets and pursue a forward-integration strategy.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Confirmation of acquisition completion by July 31, 2026.
Marksans Pharma's next financial results — check integration updates.
Future announcements regarding product launches in the German market.
LOW RISK The filing states no governmental or regulatory approvals are required, reducing transaction risk.
💡 Investor Takeaway
Marksans Pharma has entered a definitive agreement to acquire 100% share capital of ABCnow GmbH for a cash consideration of € 892,384. This acquisition provides direct sales and marketing capabilities in Germany, with ABCnow GmbH reporting a turnover of € 227,233.69 as of December 31, 2025.
⚖️ Strengths & Concerns

✅ Positives

  • Acquisition of 100% share capital of ABCnow GmbH for € 892,384 provides Marksans direct market access in Germany.
  • The transaction involves no related-party involvement and requires no governmental or regulatory approvals, indicating a straightforward process.

⚠️ Concerns

  • ABCnow GmbH's turnover was € 227,233.69 as of December 31, 2025, a decrease from € 510,215.60 in 2024.
  • ABCnow GmbH was incorporated in 2023, indicating a relatively new entity with limited operational history prior to acquisition.
❓ Frequently Asked Questions
What is the total consideration for Marksans Pharma's acquisition of ABCnow GmbH?
Marksans Pharma Limited will acquire 100% of ABCnow GmbH for a total cash consideration of € 892,384.
What is the business of ABCnow GmbH, the company acquired by Marksans Pharma?
ABCnow GmbH is a Germany-based pharmaceutical wholesale and distribution company, primarily engaged in marketing and distribution of OTC products in Germany.
What was the turnover of ABCnow GmbH as of December 31, 2025?
ABCnow GmbH had a turnover of € 227,233.69 as of December 31, 2025.
What is the expected completion timeline for Marksans Pharma's acquisition of ABCnow GmbH?
The acquisition of ABCnow GmbH by Marksans Pharma is expected to be completed by July 31, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.